Table 1. Impact of vehicle- or cisplatin-treated lung cancer cells on the chemoattraction of HUVECs.

Cisplatin concentration (µM)	HUVEC migration (% Control)
	A549	H358	cell-free
0	100.0 ± 3.6	100.0 ± 2.5	100.0 ± 8.4
0.01	64.5 ± 2.6 ***	74.9 ± 2.0 ***	114.2 ± 1.9
0.1	62.9 ± 1.8 ***	71.2 ± 3.4 ***	117.9 ± 4.2
1	56.5 ± 1.6 ***	75.4 ± 2.4 ***	119.4 ± 2.3

Following a 48-h incubation of A549 (left) or H358 (middle) cells with vehicle or 0.01 µM to 1 µM cisplatin in serum-free DMEM, the chemoattraction of HUVECs was measured using modified Boyden chamber assays. Values in the right column refer to experiments with cisplatin (in serum-free DMEM) in the lower chamber in the absence of cancer cells (cell-free). HUVECs were resuspended in serum-free DMEM and loaded onto upper chambers. Subsequently, the upper chambers were placed into the cancer cell-containing companion plates and incubated for a further 24 h prior to the read-out of migration. Values are the mean ± SEM of n = 4). ^***p < 0.001 vs. corresponding vehicle control, one-way ANOVA plus a post-hoc Dunnett test.